drugset / Trial / NCT02925533
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Phase 1
Terminated
1 enrolled
Mark Pomerantz, MD
Merck Sharp & Dohme LLC · collabRainier Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of two experimental drugs as a possible treatment for Bladder Cancer that recurred after treatment with standard therapy, or Bladder Cancer that got worse while on treatment with standard therapy. The following interventions will be involved in this study: * B-701 * Pembrolizumab
Timeline
- Start
- 2016-12-14
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Vofatamab | Monoclonal antibody | — | Intravenous |